NovoCure Ltd [NVCR] stock is trading at $18.46, up 1.48%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NVCR shares have gain 3.24% over the last week, with a monthly amount glided 9.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on July 08, 2025, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $30. Previously, Evercore ISI upgraded its rating to Outperform on December 02, 2024, and elevated its price target to $30. On October 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $30 on the stock. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to Overweight for this stock on August 08, 2023, but kept the price target unchanged to $45. In a note dated August 04, 2023, SVB Securities initiated an Outperform rating and provided a target price of $51 on this stock.
NovoCure Ltd [NVCR] stock has fluctuated between $14.17 and $34.13 over the past year. Currently, Wall Street analysts expect the stock to reach $71.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $18.46 at the most recent close of the market. An investor can expect a potential return of 287.32% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 621.71M for the trailing twelve months, which represents a growth of 11.91%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.45 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.14 points at the first support level, and at 17.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.68, and for the 2nd resistance point, it is at 18.90.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 1.47. Also, the Quick Ratio is 1.41, while the Cash Ratio stands at 0.17. Considering the valuation of this stock, the price to sales ratio is 3.31, the price to book ratio is 5.69.
Transactions by insiders
Recent insider trading involved Stafford Kristin, Director, that happened on Jun 03 ’25 when 999.0 shares were sold. Director, LEUNG GABRIEL completed a deal on Jun 03 ’25 to sell 999.0 shares. Meanwhile, Director Madden Martin J. sold 999.0 shares on Jun 03 ’25.
